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ABSTRACT 
The cannabinoid system is important for maintaining neuron-to-neuron 
communication within the mammalian brain. One of the most commonly used 
substances to alter the cannabinoid system is cannabis. Individuals who are 
exposed to cannabis report having dissociable effects; both positive and negative. 
High amounts of THC have been commonly associated with the negative effects 
of cannabis, whereas CBD can be used to counter these. Pre-clinical evidence 
suggests that the combination of the two compounds can produce a therapeutic 
benefit for individuals who are susceptible to the effects of THC. The present study 
investigates whether the combination of THC+CBD can prevent 
electrophysiological changes induced by THC. Using In Vivo electrophysiology, 
simultaneous recordings of single unit activity both in the ventral hippocampal and 
prefrontal cortex were compared after infusions of cannabinoids into the 
basolateral amygdala. THC induced changes in the PFC to increase overall activity 
whereas the combined dose of THC+CBD returned cortical activity to baseline and 
introduced a potential benefit in reduced hippocampal activity.  
 
KEYWORDS: Basolateral Amygdala, Cannabidiol, Cannabis, Delta-9 
Tetrahydrocannabinol, CB1R, Electrophysiology, Endocannabinoid, Local Field 
Potential, Prefrontal Cortex, Psychosis, Schizophrenia, Ventral Hippocampus, 
5HT-1A. 
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1.1 Introduction 
Endocannabinoid signalling in the mammalian brain is important for 
regulating the coordination of communication between brain regions to produce 
everyday behaviours. A common drug of abuse linked to alterations in this 
signalling pathway is Cannabis (i.e., Cannabis Sativa). It is well known that 
individuals can experience both positive and negative affective experiences 
following cannabis exposure. To study these effects, researchers have focused on 
two main compounds located in the plant: Delta-9-Tetrahydrocannabinol (THC) 
and Cannabidiol (CBD). The mind-altering (i.e. psychotropic) effects of cannabis 
are associated with THC, whereas CBD can treat psychosis symptoms (i.e. 
antipsychotic) (D’Souza et al., 2004; Mechoulam et al., 1988; Pertwee, 2004; 
Russo & Guy, 2006; Zuardi et al., 1982; Zuardi et al. 1991). A growing body of 
literature is now investigating how the combination of the two can prevent 
disturbances in behavioural and cognitive functioning through its effects on the 
endocannabinoid system.  
Previous studies have examined the potential therapeutic benefits of 
combined THC+CBD formulations on mental health-related behaviours using 
systemic administration routes (Boggs et al., 2017, Jacobs et al., 2016; Wright et 
al., 2013). As of yet, no clear demonstration of the combined and/or synergistic 
effects of THC and CBD has been investigated with respect to specific regions in 
the brain. As the amygdala region is involved in general endocannabinoid 
transmission and has previously produced different effects between THC and CBD 
in the human brain, we chose this as the primary region of interest in this study 
(Bhattacharyya et al., 2010; Bhattacharyya et al., 2017; Tan et al., 2010; Tan et 
al., 2011;). Furthermore, the amygdala is interconnected with both cortical and 
hippocampal regions that are impacted by THC in cognition, anxiety, memory 
(Englund et al., 2013; Lichtman et al., 1995; Jentsch et al., 1997; Rubino et al., 
2008). The work presented in this thesis is the first attempt to characterize the 
effects of THC and CBD in the amygdala of rodents using in vivo 
electrophysiological recordings. Understanding how these compounds impact 
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distant circuits provides insights in how they act on the brain to produce a potential 
therapeutic benefit when combined. 
1.1.1 The Effects of Cannabis on Mental Health  
Cannabis is currently the most commonly used illicit drug in the world. In 
2015 in Canada alone, approximately 3.6 million people report using cannabis and 
usage is expected to increase by the end of the decade (Rotermann & Macdonald, 
2018). The passing of medical marijuana laws in select states in the United States 
of America (USA) have so far seen additional rises in illicit cannabis use (Hasin et 
al., 2017). Among teenagers, legalization of medical marijuana has led to a 
decrease in perceived risk and an increased interest to recreationally use (Miech 
et al., 2015). As compounds associated with cannabis become more commercially 
available, with the continued legalization of marijuana in US states, and with 
upcoming legalization in Canada in 2018, more attention is being paid to the 
potential positive and negative health effects of cannabis use.  
 
Although symptom duration and intensity vary depending on what age one 
begins recreational cannabis use, users claim to experience acute positive benefits 
such as reduced nausea, increased relaxation, and a positive high (Mechoulam & 
Parker, 2012). In contrast, some negative effects that may occur are impairments 
in attention and memory, increased anxiety, and negative highs associated with 
psychotomimetic effects (D’Souza et al.,2004; D’Souza et al., 2005; Rottanburg et 
al., 1982; Volkow et al., 2016). These symptoms differ in duration from short-term 
to long-term; cannabis, like any drug, has the potential to alleviate or add negative 
effects. Considerable evidence now links cannabis use with alterations to the 
endocannabinoid system in the mammalian brain, causing emotional and cognitive 
dysregulation associated with various neuropsychiatric disorders (Laviolette & 
Grace, 2006; Parsons & Hurd, 2015; Volkow et al., 2016; Zehra et al., 2018). For 
example, exposure to cannabis in teenagers is associated with a greater risk for 
developing psychosis in adulthood (Arseneault et al., 2002; Arseneault, Cannon, 
Witton, & Murray, 2004; Stefanis et al., 2004). Evidence for these risks are also 
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supported in animal research. In preclinical models, adolescent exposure to 
chronic THC causes deficits in cognitive task performance associated with 
schizophrenia and psychosis (Renard et al., 2017a; Renard et al., 2017b). These 
deficits are further supported with changes in cortical and sub-cortical molecular 
signalling pathways found in animal models of schizophrenia (mTOR, GAD 67, & 
GSK). In addition, there is a growing concern about the epidemiological impact of 
increased THC content in cannabis products in the past few decades (Cascini, 
Aiello, Di Tanna, 2012). Increased ratios of THC coupled with the known 
vulnerability of adolescent populations can potentially lead to an increase in 
diagnosis rates of psychosis and schizophrenia. Cannabis use does not in itself 
cause these disorders, yet a growing body of literature finds that individuals with 
genetic (polymorphisms of COMT and AKT1) and environmental (childhood abuse 
and familial relatives with these disorders) risks for these disorders may have 
exaggerated symptom onset, duration, or intensity when chronically exposed to 
cannabis (Arendt et al., 2008; Caspi et al., 2005; Forti et al., 2012; Henquet et al., 
2009; Houston et al., 2008; Radhakrishnan et al., 2014). 
 
Central to understanding the pharmacological and psychotropic effects of 
cannabis is identifying the compounds responsible. Of over 100 phytochemicals 
contained in the plant, THC and CBD have been the most widely studied in terms 
of effects on mental health. Psychotropic effects associated with the plant have 
been linked to THC (D’Souza et al., 2004; Pertwee, 2004; Mechoulam & Parker, 
2012). Opposite to THC, CBD does not produce any mood alterations or highs on 
its own, yet it has been associated with antipsychotic and antianxiety-like benefits 
(Russo & Guy, 2006; Zuardi et al., 1982; Zuardi et al. 1991). Both compounds 
interact with the endocannabinoid system differently to alter the mammalian brain 
and produce behavioural effects (Atakan, 2012; Morales, Hurst, & Reggio, 2017; 
Pertwee, 2008;). The dissociation in the effects of cannabis may be due to the way 
the endocannabinoid system regulates the brain when the additive effects of these 
compounds interact when combined. 
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1.1.2 Endocannabinoid System 
 
The endocannabinoid system is important for proper development and 
functioning of the mammalian brain (Meyer, Lee, & Gee, 2018). This system 
contains endogenous ligands and receptors that are synthesized and expressed 
throughout the entire brain, allowing proper cell-to-cell communication between 
synapses and regulation of brain area coordination (Laviolette & Grace, 2006; 
Parsons & Hurd, 2015). Both arachidonoylglycerol (2-AG) and anandamide (AEA) 
are the most well studied endogenous ligands that act on the endocannabinoid 
system (Devane et al., 1992; Mechoulam et al., 1996). Both ligands act as 
retrograde messengers that are synthesized and released from the postsynaptic 
cell to be released into the synapse. From there, they travel to bind and activate 
cannabinoid 1 receptors (CB1R) located on presynaptic terminals. CB1Rs are one 
of the most abundant receptors found throughout the mammalian brain (Atakan, 
2012; Morales, Hurst, & Reggio, 2017). These receptors are classified as G-
protein-coupled receptors with a seven transmembrane domain. The activation of 
these receptors by these ligands blocks adenyl cyclase and downstream targets 
to prevent the release of neurotransmitter vesicles (Howlett et al., 1986). Overall, 
as cells communicate to generate postsynaptic action potentials, the 
endocannabinoid system responds by releasing 2-AG and AEA to bind to CB1R 
to cause an overall inhibition on the presynaptic cell and therefore prevents any 
dysregulation that could be caused by over excitation in the synapse (Hoffman & 
Lupica, 2000; Kano et al., 2009; Sullivan 1999; Wilson & Nicoll, 2001). In addition 
to endogenous ligands, synthesized endocannabinoids like THC can bind to CB1R 
to alter overall brain function. 
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1.1.3 Properties and Mechanisms of Delta-9 Tetrahydrocannabinol in the 
Brain 
 
The primary phytochemical responsible for the psychoactive effects of 
cannabis has been linked to THC and to changes in CB1R functioning. In 
particular, THC acts as a partial agonist for the CB1R.Because of this, THC can 
lead to different agonist-antagonist effects depending on the number of receptors 
currently expressed, the cell type, and the current presence of other endogenous 
ligands for the CB1R (Morales et al., 2017).  Despite this, THC will tend to interact 
with the CB1R like the endocannabinoids AEA, where the net result on the 
synapse is to reduce the overall exogenous release of neurotransmitter vesicles 
from presynaptic terminals (Laaris, Good, & Lupica, 2010; Shen & Thayer, 1998).   
 
As most CB1Rs are located on glutamatergic and gamma aminobutyric acid 
(GABA) expressing cells, THC will either reduce inhibition or increase disinhibition 
depending on where it is expressed (Morales et al., 2017). This will determine how 
the cannabinoid impacts brain functioning. For instance, rodents exposed to THC 
will have increased extracellular dopamine and glutamate and decreased GABA 
neurotransmitter levels measured in the PFC (Pistis et al., 2002). Glutamatergic 
release in the hippocampus is impaired but can be reversed with the presence of 
CB1 antagonists (Fan et al., 2010). THC can also increase striatal dopamine 
release, similar to other drugs of abuse, via CB1R and therefore lead to emotional 
salience misattributions and distortion (Wijayendran et al., 2016). In addition, THC 
administered to prenatal fetuses or during adolescence results in abnormal 
development of glutamatergic and dopaminergic signalling in the rodent brain to 
impact cognition and attention (Castaldo et al., 2007; Renard et al., 2016, Renard 
et al., 2017a; Renard et al., 2017b). 
 
The interaction of these various neurotransmitter systems during exposure to 
THC can alter cognitive and behavioural functioning in the mammalian brain. For 
example, in rodents, THC can cause greater errors in working memory 
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performance, which is reversed with a CB1 antagonist (Lichtman & Martin, 1996). 
In both young and adult rodents, systemic THC produces an anxiogenic effect as 
measured in the elevated plus maze, light-dark, and open field locomotion tasks 
(Sapyta et al., 2007). In humans, a single administration of intravenous THC can 
cause healthy individuals to feel increased anxiety, verbal working memory 
impairments, positive, negative, cognitive and psychosis-like symptoms, along 
with feelings of a high (D’Souza et al., 2005). Furthermore, individuals with a 
history of psychotic symptoms experience similar deficits after acute THC 
administration (D’Souza et al, 2006). Chronic exposure to THC during critical 
neurodevelopmental periods is associated with schizophrenia-like deficits in 
adulthood, coupled with a loss in cortical interneurons and modulation of the 
mesolimbic system (Renard et al, 2017a; Renard et al., 2017b).  
 
Cortical overexcitation via loss of inhibitory interneuron regulation may result in 
dysregulated GAMMA oscillatory activity, a neuropathological feature associated 
with schizophrenia (Lee et al., 2010; Symond et al. 2005). Furthermore, 
administration of THC can alter GAMMA oscillations in both the prefrontal cortex 
and the hippocampus, two regions that are involved with schizophrenia (Renard et 
al., 2017a; Renard et al., 2017b; Robbe et al., 2006;). Studying how THC alters 
the endocannabinoid system is therefore important to understanding how mal-
adaptive effects can arise from use in healthy and clinical populations.  
 
1.1.4 Properties and Mechanisms of Cannabidiol in the Brain 
 
In contrast to THC, CBD has very low affinity as a CB1 receptor antagonist 
(Thomas et al., 2009), leading researchers to search for alternative sites of action 
to explain its effects. CBD can act as a partial agonist to the 5HT-1A serotonin 
receptor (Pertwee, 2004; Russo et al., 2005), a weak partial agonist for D2 
receptors (Seeman et al., 2016), a weak negative allosteric modulator to Mu opioid 
receptors (Kathmann et al., 2006) and activates the GPR55 receptor (Ryberg et 
al., 2007). Recently, researchers have focused on CBD’s involvement with the 
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5HT-1A receptor to regulate cell-to-cell communication. In general, activation of 
the 5HT-1A autoreceptors located on post synaptic somato-dendritic sites causes 
inhibition of that cell’s firing output (Polter & Li, 2010; Tada et al., 2004;). Following 
this cell firing inhibition, CBD administration could potentially inhibit post-synaptic 
transmission and therefore impact the activity of projected areas. For instance, 
intracranial infusion of CBD in the shell of the nucleus accumbens (NASh) can 
attenuate ventral tegmental area (VTA) dopamine neuron firing (Norris et al., 2016; 
Renard et al., 2016). 
 
Similar to THC, the effects of CBD are determined by the location of its 
target receptors, with activation in different brain regions potentially causing 
different behavioural effects. Although CBD does not show any psychotropic 
effects, research has linked its potential in having anxiolytic, anti-inflammatory, and 
anti-psychotic-like properties (Russo & Guy, 2006; Zuardi et al., 1982; Zuardi et al. 
1991). Anxiolytic effects of CBD have been associated with behavioural changes 
in forced swim tasks (Sartim et al., 2016), elevated plus maze tasks (Campos and 
Guimares, 2008), facilitating fear extinction (Bittencourt et al., 2008; Do Monte et 
al., 2013), and impairing fear-associated memories (Gomes et al., 2010, Norris et 
al., 2016, Stern et al., 2017). CBD has also shown antipsychotic-like benefits by 
reducing sensory-motor gating deficits (Renard et al., 2016), preventing short-term 
THC-induced memory and social interaction impairments (Malone et al., 2009; 
Morgan et al., 2010), and dopamine-related psychomotor sensitization (Renard et 
al., 2016). Although very few clinical trials exist in the literature, research 
demonstrates that daily oral doses of CBD administered to schizophrenic 
populations exhibit improvements in negative and cognitive symptoms comparable 
to those treated with traditional antipsychotic medication (Leweke et al., 2012). The 
normal circulation of endocannabinoid levels can also interact with CBD. Acute 
administration of CBD increases overall AEA levels by blocking reuptake and fatty 
acid amide hydrolase inhibition (Bisogno et al., 2001; Ligresti et al., 2006). This 
effect on increased release of AEA in the synapse would reduce the overall release 
of neurotransmitter vesicles from presynaptic terminals, and therefore inhibit cell-
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to-cell communication (Hoffman & Lupica, 2000; Kano et al., 2009; Sullivan 1999; 
Wilson & Nicoll, 2001). Due to its interactions with the endocannabinoid system 
and the independent benefits that it might have on behaviour, CBD appears to 
have therapeutic potential for users.   
 
1.1.5 Therapeutic potential of combined THC and CBD formulations 
 
Although the mechanisms underlying CBD’s ability to interact with the 
endocannabinoid system are still being characterized, growing evidence suggests 
that it may be used to counter some of the negative side effects of THC use. In 
non-human primates, THC+CBD ratios of 1:1 and 1:3 can reverse temporary THC-
induced cognitive and visuospatial attention impairments (Jacobs et al., 2016; 
Wright et al., 2013). Pre-treatment at a systemic 1:20 ratio can prevent the social 
interaction deficits associated with THC (Malone et al., 2009). Furthermore, THC-
induced conditioned place aversion can be blocked at a 1:1 combined CBD ratio, 
despite it having no preference effects by itself (Vann et al., 2008).  
 
In human studies, the dose used to demonstrate CBD’s potential restorative 
effects is much higher. For example, individuals given 10mg of THC display 
increases in skin conductance responses and subjective anxiety ratings to fear 
stimuli whereas CBD alone (at 600mg) does not elicit any change compared to 
placebo (Fusar-Poli et al., 2009). In recreational users, those who smoked 
cannabis with higher CBD to THC concentrations did not display impairments on 
memory in contrast with those who had lower concentrations of CBD and did have 
memory issues (Morgan et al., 2010). In healthy participants, THC IV infusions 
cause deficits in hippocampus-dependent episodic memory performance but pre-
treatment with 600mg CBD improved performance to placebo levels (Englund et 
al., 2013). In addition, a 1:2 oral dose combination prevented THC-induced 
impairments in emotional facial recognition (Hinodocha et al., 2015). Although 
more studies are needed, considerable evidence suggests that CBD may prevent 
some of the neuropsychiatric effects seen with THC, yet not in all situations. In 
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some situations, CBD can induce an effect independent of the presence of THC, 
for instance CBD is able to block fear memory reconsolidation with or without THC 
(Stern et al., 2012; Stern et al., 2015). This could suggest that CBD can prevent 
THC deficits in some cases and act on the brain independently of THC in other 
cases. Furthermore, some ratios of THC:CBD may even allow a user to experience 
a higher dose of THC while avoiding some of the negative side-effects (Boggs et 
al., 2017). Overall, CBD’s potential to prevent or reverse the effects of THC when 
combined may depend on the dose ratio and the animal species researched.  
 
1.2 Cannabinoid modulation of the basolateral amygdala, ventral 
hippocampus, and prefrontal cortex 
 
The endocannabinoid system is involved with multiple brain regions that are 
important for regulating cognition, emotion, memory, and anxiety (Laviolette & 
Grace, 2006; Mechoulam & Parker, 2012). The interference of these processes 
from cannabis may be a result of how THC and CBD potentially interact within 
these regions. For example, in chronic cannabis users, CB1Rs are downregulated 
in areas such as the hippocampus and PFC, which are important for cognition and 
memory (Hirvonen et al., 2011). Structural neuroimaging and resting state studies 
have also shown reductions in hippocampal, prefrontal cortex, and amygdala brain 
volume and activity in chronic cannabis users (Block et al., 2000; Yucel et al., 
2008). Furthermore, acute administration of CBD has been shown to decrease 
blood oxygenated levels in both the amygdala and hippocampus (De Crippa et al., 
2004).  All three regions are comprised of the mesolimbic system, which has been 
implicated in reward, learning, anxiety, and cognition (Laviolette, 2017). It is 
therefore important to understand how these regions are influenced by 
phytocannabinoid exposure to determine how THC and CBD may produce their 
differential effects on the brain and neuropsychiatric phenomena. 
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1.2.1 Cannabinoid Effects on the Basolateral Amygdala 
 
Anatomically, the amygdala is clustered into functionally distinct regions. 
The Basolateral Amygdala (BLA) is one area considered important for emotion and 
anxiety regulation (Janak & Tye, 2015). The BLA has cortical-like features, as it is 
compromised of two main cell types: glutamatergic pyramidal projection neurons 
and GABAergic local interneurons (Ramikie et al., 2012). The CB1R is highly 
expressed in the BLA, with mRNA studies revealing that approximately 95% of 
cells co-express GABAergic markers (Marsicano & Lutz, 1999). This suggests its 
predominant expression is on BLA interneuron terminals. Given the location of 
these receptors, activation via cannabinoid transmission decreases spontaneous 
and evoked transmission on the BLA pyramidal neurons (Katona et al., 2001). 
Therefore, activation of these CB1Rs is predicted to indirectly increase pyramidal 
neuron firing by decreasing GABA interneuron inhibition, therefore causing an 
increase in activity to downstream targets of the BLA (Ramikie et al., 2012).  
 
Efferent projections from the BLA go to multiple neural regions, but of most 
importance to this study are those going to the hippocampus and PFC (Knapska 
et al., 2007; Sah et al., 2003). For example, cannabinoid-mediated modulation of 
these specific pathways can alter anxiety and emotional memory processing 
(Felix-Ortiz et al., 2014; Laviolette & Grace, 2006). In addition, being 
interconnected with these regions positions the BLA as a central structure involved 
in coordinating salient environmental stimuli and consolidating that information to 
form emotional memories.  
 
Considerable evidence demonstrates that cannabinoid transmission within 
the BLA can affect emotion regulation and memory. Activation of intra-BLA CB1Rs 
via an agonist will potentiate the acquisition of a fear memory, whereas a CB1R 
antagonist has been shown to block the formation of emotional associative 
memories (Tan et al., 2011). Endocannabinoid-mediated activation in the BLA also 
causes animals to have increased anxiety and prevents the formation of aversive 
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memories (Munguba et al., 2011). Micro-infusions of THC into the BLA alters 
memory and causes an anxiogenic effect on elevated plus maze and locomotion 
tasks (Rubino et al., 2008). Furthermore, activation of CB1R in the BLA can switch 
morphine’s rewarding effects into aversive memory place preferences (Ahmad et 
al., 2016). In humans, acute oral administration of THC in healthy subjects not only 
increases anxiety and symptoms associated with psychosis but can cause an 
increased blood oxygenated level in the amygdala when viewing negative stimuli 
(Bhattacharyya et al., 2017). This effect was correlated with PET imaging 
expression of CB1R in the amygdala, demonstrating the connection between the 
effects of THC on emotional stimuli mediated through the cannabinoid receptor. 
The same lab previously showed that an oral dose of CBD did not produce any 
changes in the same behavioural measures relative to placebo, but found a 
significant decrease in amygdala BOLD signalling compared to THC 
administration (Bhattacharyya et al., 2010). These findings suggest that both CBD 
and THC can have independent effects on amygdala activity to alter affective 
processing and associated behaviours.  
 
1.2.2 Effects of Cannabinoids in the Ventral Hippocampus 
 
The hippocampus’ involvement in regulating emotion, stress, and learning 
and memory processes makes it a potential target for the effects of cannabis use. 
In particular, the ventral hippocampus is more involved with emotion and anxiety 
phenomena as opposed to the dorsal region, which is important for spatial and 
contextual memory processing (Fanselow & Dong, 2010). The ventral 
hippocampus region in rodents is functionally analogous to the anterior 
hippocampus in humans (Fanselow & Dong, 2010). Reductions of anterior 
hippocampal volume occur in chronic cannabis users, with the most severe 
reductions in individuals exposed to higher ratios of THC to CBD (Demirakca et 
al., 2011).  
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Within the ventral hippocampus, cannabinoid transmission is important in 
regulating salience of environmental cues and in emotional memory formation. 
Similar to the BLA, CB1R expression is mainly located on GABAergic interneurons 
(Katona et al., 1999), which can cause an overexcitation towards the system via 
interneuron inhibition when activated. Considerable evidence now suggests that 
overexcitation of vHPC is responsible for behavioural deficits associated with 
schizophrenia (Grace et al., 2010). For example, intracranial microinjections of a 
CB1R agonist into the hippocampus impairs performance on radial arm maze 
memory tasks similar to the effects seen with systemic THC (Lichtman et al., 1995). 
Systemic THC and WIN55 (i.e., a full CB1R agonist) cause impairments in a 
delayed nonmatch sample task which simultaneously co-occurs with alterations in 
hippocampal cellular firing (Hampson & Deadwyler, 2000). A high dose of THC (5 
ug) injected into the vHPC makes rodents more anxiolytic on the elevated plus 
maze task (Rubino et al., 2008). Direct activation of the CB1R using WIN55 in the 
vHPC can potentiate the acquisition of both reward and fear memories at non-
rewarding or low foot shock conditions while also impairing social recognition 
(Loureiro et al., 2015). This potentiation of non-salient cues is associated with 
changes in the mesolimbic system with vHPC micro infusions of WIN55 increasing 
activity in both NASh medium spiny and VTA dopamine neurons (Loureiro et al., 
2015; Loureiro et al., 2016). Furthermore, THC can also impact single unit and 
local field potential (LFP) recordings in awake animals. Both systemic and 
intracranial hippocampus injections of a CB1 full agonist decreases power for LFP 
across Theta, Gamma, and Ripple events (Robbe et al., 2006). Although single 
unit recordings were not analyzed, systemic injections of THC also decreased LFP 
power in the same frequency bands (Robbe et al., 2006). Acute administration of 
THC can reduce resting state ventral hippocampal activity, further implicating the 
compound as a potential anti-psychotic to counter overexcitation of the circuit (De 
Crippa et al., 2004).  
 
Alterations from the vHPC can therefore impact other regions that are 
interconnected. The vHPC shares unique neuronal connectivity between the PFC 
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and the amygdala, unlike the dorsal hippocampus. Specifically, ventral 
CA1/subiculum regions of the ventral hippocampus have re-occurring connections 
with the posterior BLA and prelimbic regions of the PFC (Pitkanen et al., 2000; 
Cenquizca & Swanson, 2007). This pathway, along with known properties of BLA 
cannabinoid transmission, makes the ventral hippocampus an interesting target to 
examine the local effects of THC and CBD administration in the context of 
mesocorticolimbic circuitry.  
 
1.2.3 Effects of Cannabinoids on the Prefrontal cortex 
 
The prefrontal cortex is an important region to study the effects of 
cannabinoid drugs on cognition, attention, and memory. In rodents, the pre-limbic 
region of the PFC is interconnected with the BLA, potentially implicating this 
pathway as important for endocannabinoid transmission (McGarry & Carter, 2017; 
Tan et al., 2010; Tan et al., 2011). Similar to the BLA and vHPC, CB1R is highly 
expressed within the PFC interneuron populations. Endocannabinoids, when 
expressed in the pre-limbic regions of the PFC, can inhibit evoked excitatory 
postsynaptic currents and therefore impact other interconnected regions 
(Lafourcade et al., 2007). In addition, THC given systemically can also cause an 
increase in mRNA expression in the PFC for c-fos, a marker for neuronal activation 
(Egerton et al., 2001). In humans, the PFC and anterior cingulate have increased 
blood oxygenated levels after smoking cannabis (Kanayama et al., 2004). All these 
changes in the PFC can have implications for behavioural task performance. 
Working memory tasks such as the T-maze and radial arm maze require the 
prefrontal cortex to maintain and make decisions based on cues found in the 
environment. Systemic injections of THC cause impairments on these working 
memory tasks (Jentsch et al., 1997; Lichtman et al., 1996). Low doses of THC 
micro-infused into the PFC surprisingly makes an animal more anxiolytic, in 
contrast to high doses that produce an anxiogenic effect (Rubino et al., 2008). 
Activation of CB1R with low doses of a full agonist can also potentiate the 
acquisition of a subthreshold fear memory (Draycott et al., 2014). Combined these 
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findings suggest that the PFC is a region susceptible to endocannabinoid 
modulation and that unique connections shared with both the vHPC and BLA make 
it a region of special interest in the neural circuitry described below. 
 
 1.2.4 Cannabinoid modulation of the vHIPP-PFC-BLA circuit 
 
As discussed above, the cannabinoid signaling system, through either 
endogenous or exogenous compounds, can substantially alter behaviour and 
neuronal functioning separately in the BLA, vHPC, and PFC (Draycott et al., 2014; 
Loureiro et al., 2015; Loureiro et al., 2016; Robbe et al., 2006; Tan et al., 2011). 
However, each area functions independently and is part of a dynamic system with 
recurring connections between these regions. The effects of cannabis, specifically 
THC, may alter how each region coordinates with other regions. For instance, 
systemic THC decreased functional connectivity between the amygdala and PFC 
in humans, during poor performance on the re-appraisal of negative stimuli 
compared to controls (Gorka et al., 2015). Oral administration of CBD can also 
decrease at rest BOLD signalling in both the amygdala and hippocampus (De 
Crippa et al., 2014).  
 
In rodents, systemic THC can alter neuronal activity in the PFC and vHPC 
(Aguilar et al. 2016; Robbe et al., 2006). One study found that average firing rates 
of single unit neurons in the PFC decreased, whereas no change was found in 
cells recorded in the ventral hippocampus (Aguilar et al., 2016). Furthermore, THC 
increased coherence between both regions in the Delta frequency band which is 
associated with activity at rest. A caveat to this study was that no consideration 
between cell types were controlled for during single unit recordings. Therefore, the 
combined activity of principal and interneuron populations could have possibly 
masked any independent effects under the presence of THC. In the current 
literature, no study has yet addressed how THC can alter single unit populations 
in both the vHPC and PFC. Furthermore, the combination of THC+CBD has yet to 
be explored in the modulation of neural circuit dynamics in the mammalian brain. 
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1.3 Research Aims and Hypothesis 
 
The endocannabinoid system is critical for the proper health and 
development of the mammalian brain (Meyer, Lee, & Gee, 2018). Mental health 
disorders such as schizophrenia have been linked to disruption of the 
cannabinoid system in mesolimbic areas of the brain (Laviolette & Grace, 2006). 
One pathological manifestation of schizophrenia is persistent thoughts of 
hallucinations and delusions. Cannabinoid compounds may modulate the 
mesolimbic system and may be partially responsible for inappropriately 
reinforcing the distorted emotional significance of everyday events within the 
schizophrenic population (Laviolette & Grace, 2006).  
 
To investigate this hypothesis, our research group has tested how THC can 
modulate the cannabinoid system within mesolimbic areas of the brain. In the BLA, 
PFC, and vHPC, we demonstrate that THC, or the activation of its target receptor, 
CB1R, can impair cognition, anxiety, sociability, learning and memory, and reward-
related behaviours (Ahmad et al., 2016; Draycott et al., 2014; Loureiro et al., 2015; 
Loureiro et al., 2016; Renard et al., 2017a, Renard et al., 2017b; Tan et al., 2010, 
Tan et al., 2011). Building on this research, we wish to investigate how to prevent 
these impairments by countering the effects of THC. As previously discussed, CBD 
combined with THC can restore impairments in cognition, attention, sociability, 
anxiety and emotional processing (Englund et al., 2012; Fusar-Poli et al., 2009; 
Jacobs et al., 2016; Malone et al., 2009; Wright et al., 2013). Therefore, this 
phytocannabinoid combination has potential therapeutic benefits in select 
behavioural paradigms and neuropsychiatric tests. However, the precise 
mechanisms by which CBD may counteract the effects of THC on brain circuits 
linked to cannabis-related neuropsychiatric disorders has not yet been clarified. 
 
Our research group has previously demonstrated that cannabinoid 
transmission in the BLA can alter pyramidal cell activity in the PFC (Tan et al., 
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2010; Tan et al., 2011). This was done using a full, synthetic CB1R agonist, 
WIN55,212-2, as a method to modulate the endocannabinoid system. However, 
we have not yet examined how the effects of plant-derived, pure THC (a partial 
agonist of the CB1R), may alter neuronal activity states in the PFC. Furthermore, 
systemic administration of THC can induce changes in the single unit and local 
field measures between the PFC and vHPC (Aguilar et al., 2016). Given the 
position of the BLA as a region that projects directly to both areas (Knapska et al., 
2007; Sah et al., 2003), we wanted to explore how THC might impact this circuitry. 
Furthermore, CBD can act as a potential therapeutic when combined with THC 
and independently it can alter neuronal activity of other regions in the mesolimbic 
system such as the NASh (Boggs et al., 2017; Norris et al., 2016). The current 
literature has yet to explore whether the combination of THC+CBD can reverse 
electrophysiological changes induced by THC.  
 
My overarching hypothesis is that acute exposure to THC in the BLA 
is sufficient to cause an overexcitation of both ventral hippocampal and 
prefrontal cortex as reflected by increased neuronal and oscillatory activity 
states and that co-administration of CBD will prevent this effect. 
   
In this thesis, I have addressed this hypothesis with the following specific 
experimental aims:  
1) Characterize the effects of intra-BLA THC administration on 
single unit and LFP activity in the PFC. 
 
2) Characterize the effects of intra-BLA THC administration on   
single unit and LFP activity in the vHPC. 
 
3)  Determine if CBD co-administration with THC can block the 
effects of THC alone on the PFC-vHPC circuit.  
  
  17 
 
 
 
2. Methods 
 
2.1 Animals and Housing 
 
 Adult male Sprague-Dawley rats were obtained from Charles River 
(Quebec, Canada) and maintained an average weight of 300-400g on testing day. 
Rodents were pair housed in a temperature controlled 12-hour light-dark cycle at 
the animal care facility at the University of Western Ontario. Water and food were 
given ad libitum and housing conditions consisted of being placed in a plexiglass 
box with corn bedding and environmentally enriched objects (chewing wood 
blocks, paper towel, and paper nesting material).  
 
2.2  In Vivo Electrophysiology 
 
All methods for preparation of single unit recordings in the PFC and vHPC 
follow protocols previously described (Laviolette et al., 2005). All recordings were 
performed under urethane anesthesia (1.5/kg, i.p, Sigma-Aldrich) and rodents 
were placed in a stereotaxic frame with a heat pad to maintain a body temperature 
of 37 degrees Celsius. Scalpel incisions were made on the surface of the head 
and holes were drilled in the skull overlying on the targeted structures of the study: 
mPFC (AP: +3mm, L+/- 0.8 to +/ 1mm, DV -2.5 to -4.5 mm from the dural surface), 
BLA (AP: -3.0mm, L=/- 5.0mm, DV - 7.4mm from dural surface), and vHPC (AP: -
5.6, ML: 5, DV:(-6-7.5mm).  
 
Electrodes were pulled from borosilicate glass with an average impedance 
of 6 and 8 MΩ and were filled with 2% Pontamine Sky Blue solution (Sigma-
Aldrich). For recordings, extracellular signals were amplified using a MultiClamp 
700B amplifier (Molecular Devices) and recorded using a Digidata 1440A 
acquisition system (Molecular Devices) with pCLamp 10 software. Two channels 
were used (PFC channel 1 and vHPC channel 2) and were sampled to obtain both 
single unit recordings (bandpass 0.5 and 3 kHz) and local field potentials (low pass 
at 0.3 kHz). Micro electrodes were connected to the channels via a tungsten wire 
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and electrodes were slowly inserted to both areas of the brain. Once in, electrodes 
were left to rest for fifteen minutes before searching for isolated recordings. 
Baseline spontaneous activity was recorded for at least 5 minutes before micro 
infusions of drugs into the BLA.  
 
Neuroexplorer (Nex Technologies) was used for LFP, crosscorrelation, and 
coherence analysis. Preprocessing consisted of decimating the signal to 1kHz and 
low pass filtering (IIR butterworth filter at 100, filter order 3, 0.5 shifts in a 2 s 
window. Spectrogram analysis settings pre-processed data with a maximum 
frequency of 100, 2048 frequency values, normalized to raw PSD. Oscillations 
were segmented based on frequency range: Delta (0.5-4Hz), Theta (4-7Hz), Alpha 
(7-14Hz), Beta (14-30Hz), Low Gamma (30-58Hz), and High Gamma (62-80Hz). 
 
 Both crosscorrelation and coherence analysis are statistical tests used to 
assess the degree of connectivity between multiple regions. In this case, both tests 
were used to determine whether LFP signals in the vHPC co-occurred with LFP 
signals in the PFC across recording sessions. For the auto-correlation, the vHPC 
signal was correlated in reference to the PFC signal and averaged across a five-
minute baseline to produce a single data point. This was repeated to obtain a data 
point for a five-minute post-drug infusion period. Both values are represented as a 
correlation value, with the highest possible crosscorrelation 1.0 representing both 
LFP signals completely overlapping at the same time point. Using a repeated 
measures ANOVA, both correlation values are compared between groups to 
determine changes in PFC-vHPC LFP signal overlap. The coherence analysis 
takes a similar approach but differs in two respects. First, it compares vHPC to 
PFC signal overlap as a function of frequency (Delta, Theta, Alpha, Beta, & 
Gamma). Thus, data points obtained are restricted to each oscillation range. 
Second, more than one data point is obtained with respect to each oscillation range 
because this analysis is not restricted to using data at the same time-point. Instead 
it looks at overlap across the entire five-minute baseline compared to the entire 
five-minute post-infusion period. Therefore, crosscorrelation compares overlap 
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between PFC-vHPC at the same time point whereas coherence is only interested 
in total signal overlap within each oscillation range. 
 
PFC pyramidal cells were identified based established criteria of firing 
frequency (<10 Hz), waveform shape, duration of action potential (> 2.5 ms), and 
burst firing. Bursting patterns were identified when a cell fires 3 consecutive spikes 
with an inter-spike interval of <45ms.  Percentage of burst spike count was 
determined by dividing the total bursts by the total amount of spikes in the same 
five-minute period. Selection for vHPC principal neurons in the current dataset 
were for cells that had baseline firing rates of 0.5-5hz (Goonawardena, Riedel, & 
Hampson, 2011). The total sample of animals used in each group are: Vehicle N 
= 8, THC N = 9, CBD N = 8, THC+CBD 100ng:100ng N = 10, THC+CBD 
100ng:500ng N = 4, CBD 500ng N = 3.  
 
2.3 Drug Preparation 
 
Both THC (Cayman Chemical) and CBD (Tocris) were used in the study. 
THC stored in ethanol was dissolved in cremophor and saline (1:1:18). Ethanol 
was evaporated from the working solution through evaporation nitrogen gas.  CBD 
in powder form was dissolved in cremophor and then into saline. Both THC and 
CBD mixtures independently and combined consisted of a final concentration of 
5% cremophor in the working solution. Drugs were micro infused into the BLA with 
a microinjector (Hamilton Syringe 10 ul) at a volume of 0.5 ul slowly over one 
minute.  
 
2.4 Histology 
  
Upon completing electrophysiological recordings, rodent brains were 
extracted and placed in a 10% formalin solution for at least 24 hours. Then brains 
were moved to a formalin-sucrose solution for at least 5 days. Brains were sliced 
at 60 µm and mounted on slides. Slides were then stained with neutral red (Sigma 
Aldrich) and placements for BLA, vHPC, and PFC were verified using light 
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microscopy. Any rodents showing placements outside the boundaries defined by 
Paxinos and Watson (2005) were excluded from data analysis.  
 
2.5 Statistical Analyses 
  
Electrophysiological data were analyzed with either a one or two-way 
ANOVA where appropriate. Post hoc analyses were performed using Fisher’s LSD 
tests.  
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3. Results 
 
3.1 Histological Analyses 
 
Analysis of histology revealed the Hamilton syringe placements to be 
localized in the anatomical boundaries of the BLA according to the Rat Brain Atlas 
(Paxinos & Watson, 1996). Pontamine blue dot and electrode tracks were used to 
confirm placements of the last recorded cell in the anatomical boundaries of both 
the prelimbic regions of the PFC and vHPC. Figure 1A presents a microphotograph 
displaying a representative placement within the PFC. Figure 1B displays a 
schematic illustration showing representative PFC placements along the rostral-
caudal axis. Figure 1C presents a microphotograph of injector placements in the 
BLA. Figure 1D displays a schematic illustration of rostral-caudal placements 
within the BLA. Figure 1E is a representative microphotograph of a placement 
within the vHPC. Figure 1F displays a schematic illustration of rostral-caudal 
placements within the vHPC. 
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Figure 1. Histological analysis of BLA injection and PFC & vHPC recording sites. A) 
Microphotograph of a presentative PFC recording site. B) Schematic representation of PFC 
recording locations. C) Microphotograph of representative BLA injection site. D) Schematic 
representation of BLA injector locations. E) Microphotograph of vHPC recording sites. F) 
Schematic representation of vHPC recording locations. Symbols:    Vehicle,   THC 100ng,     CBD 
100ng,      CBD 500ng,     THC+CBD 100ng:100ng,     THC+CBD 100ng:500ng. 
 
3.2 The effects of BLA cannabinoid administration on PFC Single Unit 
activity 
 
A one-way ANOVA comparing the mean firing rates of single unit activity 
revealed THC significantly increased pyramidal cell firing in the PFC. Overall, there 
was a significant difference between groups (F(5,95) = 2.453, p = 0.039). Following 
this, a Fisher’s LSD post-hoc test comparing groups means revealed that infusion 
of THC into the BLA significantly increased pyramidal cell firing compared to 
vehicle (p = .008), CBD 100 ng (p = .003), THC+CBD 100ng:100ng (p = .039), 
THC+CBD 100ng:500ng (p = .011), and CBD 500 ng (p = .013) infusions. When 
CBD was combined with THC at both ratios, this blocked the THC mediated 
increase. All other groups that contained CBD showed no increase compared to 
vehicle. In addition, a one-way ANOVA comparison on PFC single unit bursting 
rate found a significant difference, F(5,95) = 3.458, p = .006, where THC infusions 
increased bursting firing compared to all other groups (i.e., Vehicle p = .001, CBD 
100 ng p < .001, THC+CBD 100ng:100ng p < .003, THC+CBD 100ng:500ng p = 
.004, and CBD 500ng p = .003). Once again, all other groups were no different 
compared to vehicle.  
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Figure 2. In vivo single unit recording activity in the PFC. A) Representative rastergram showing 
firing frequency of PFC pyramidal cell neurons during intra-BLA THC microinfusion. B) Percentage 
of cells within each group classified as cells that increase more than 10%, decrease more than 
10%, and cells that do not change beyond +/-10%. C) Percentage difference in mean firing rates. 
* indicates significantly different from all groups. D) Percentage change in mean bursting rates. * 
indicates significantly different from all groups. Sample size: Vehicle (N=17), THC 100ng (N=17), 
CBD 100ng (N=20), THC+CBD 100ng:100ng (N=20), THC+CBD 100ng:500ng (N=15), CBD 500ng 
(N=12). 
 
3.3 The effects of BLA cannabinoid administration on vHPC Single Unit 
activity 
 
Overall, all groups containing CBD decreased ventral hippocampus 
principal cell firing. A one-way ANOVA comparing mean firing rates of ventral 
hippocampal single unit activity found a significant difference between groups 
(F(5,103) = 4.575, p = 0.001). A follow up Fisher’s LSD post-hoc test compared all 
groups revealing Vehicle and THC infusions and they were not significantly 
different from one another, p = .699. In contrast, Vehicle infusions were 
significantly different from all groups that contained CBD: CBD 100ng, p = .015, 
THC+CBD 100ng:100ng, p = .007, the THC+CBD 100ng:500ng, p < .001, and 
CBD 500ng, p = .002. BLA infusions of THC were also significantly different from 
all groups that contained CBD: CBD 100ng, p = .37, THC+CBD 100ng:100ng, p = 
.007, THC+CBD 100ng:500ng combination, p = .001, CBD 500ng, p = .007. All 
groups containing CBD were not significantly different from one another. 
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Figure 3. In vivo single unit recording activity in the vHPC. A) Representative histogram showing 
firing frequency of vHPC principal cell neurons during intra-BLA THC+CBD microinfusion. B) 
Percentage of cells within each group classified as cells that increase more than 10%, decrease 
more than 10%, and those that have neither directional change within 10%. C) Percentage 
difference in mean firing rates. * indicates significantly different from vehicle and THC. Sample size: 
Vehicle (N=14), THC 100ng (N=15), CBD 100ng (N=20), THC+CBD 100ng:100ng (N=27), 
THC+CBD 100ng:500ng (N=18), CBD 500ng (N=15).   
 
3.4 The effects of BLA cannabinoid administration on PFC LFP activity 
 
Given significant differences at the single unit level, we then analysed data 
at the local field potential level. This analysis involved comparing all six groups 
across six oscillation ranges (Delta, Theta, Alpha, Beta, Low Gamma, and High 
Gamma). Overall, THC caused an increase in power for low and high Gamma. For 
low Gamma (i.e., 62HZ-80HZ), a one-way ANOVA found a significant difference, 
F(5, 85) = 2.442, p = .041 across groups where both THC 100ng and THC+CBD 
100ng:100ng were significantly different from Vehicle (p= .037; p = .038) and CBD 
100ng (p= .011; p = .010). For High Gamma, a one-way ANOVA found a significant 
difference, F(5, 85) = 3.524, p =.006 across groups where only THC significantly 
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increased power post-infusion compared to all other groups (i.e., Vehicle p = .002; 
CBD 100ng p= .001, THC+CBD 100ng:100ng p = .001, THC+CBD 100ng:500ng 
p= .002, CBD 500ng p= .003). One-way ANOVA analysis revealed no significant 
differences between groups across Delta (F(5, 85) = 1.697, p = .144), Theta (F(5, 
85) = .652, p = .661), Alpha (F(5, 85) = .855, p = .515), and Beta (F(5, 85) = 1.201, 
p = .316). 
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Figure 4. Local Field Potential recordings in the PFC. A) Diagram of a representative cell’s LFP 
total power across 0-100 HZ oscillation range. Orange is total power across five minutes after 
infusion of THC. B) Spectrogram depicting change in power in the high gamma oscillation (62-80 
Hz). C) Change in LFP averaged across groups in low gamma range. * indicates significantly 
different from vehicle and CBD 100ng. D) Change in LFP average across groups in high gamma 
range. * indicates significantly different compared to all groups. Sample Size: Vehicle (N=16), THC 
100ng (N=16), CBD 100ng (N=20), THC+CBD 100ng:100ng (N=20), THC+CBD 100ng:500ng 
(N=15), CBD 500ng (N=12).   
 
3.5 The effects of BLA cannabinoid administration on vHPC LFP activity 
This next section compared LFP difference in the vHPC. A one-way ANOVA 
analysis revealed no significant difference between groups across Delta (F(5, 88) 
= .486, p = .786)), Theta (F(5, 88) = 1.946, p = .095)), Alpha (F(5, 88) = 1.167, p = 
.332), Beta (F(5, 88) = .424, p = .831)), Low Gamma (F(5, 88) = .929, p = .466)), 
and High Gamma (F(5, 88) = .174, p = .972)) oscillations. Therefore, THC had no 
single unit effect and no change in LFP in the ventral hippocampus. CBD, in 
comparison to single unit recordings, did not alter LFPs in the ventral 
hippocampus. 
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 Figure 5. Local Field Potential recordings in the vHPC. A) Change in LFP averaged across groups 
in low gamma range. B) Change in LFP averaged across groups in high gamma range. Sample 
size: Vehicle (N=16), THC 100ng (N=16), CBD 100ng (N=20), THC+CBD 100ng:100ng (N=20), 
THC+CBD 100ng:500ng (N=15), CBD 500ng (N=12).   
 
 
3.6 Crosscorrelation Analysis between PFC and vHPC 
 
After analyzing the local field potential within a region, we decided to 
compare changes between regions. This analysis looks at whether THC or CBD 
alters crosscorrelations or coherence levels between the PFC and vHPC. A two-
way repeated measures ANOVA revealed no overall main effect between pre-
infusion and post infusion times, F(1, 129) = .550, p = .460. In addition, no within-
subjects interaction between groups and infusion time were revealed in the data 
set, F(5,129) = .099, p = .992. 
 
 
 
Figure 6. PFC-vHPC Crosscorrelation. A) Correlogram of Crosscorrelation scores between PFC 
and vHPC connectivity. Sample size: Vehicle (N=20), THC 100ng (N=21), CBD 100ng (N=33), 
THC+CBD 100ng:100ng (N=23), THC+CBD 100ng:500ng (N=21), CBD 500ng (N=17).   
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3.7 Coherence Analysis between PFC and vHPC 
 
For our final analysis, we divided the data within each oscillation range and 
compared between PFC-vHPC activity using a coherence analysis. Overall, there 
was no significant difference in a two-way ANOVA across all oscillation ranges. 
Time is listed as the variable between pre- and post-infusion. Overall, the analysis 
revealed no significant main effect for Delta time (F(1,127) = 1.649, p = .201)) or 
interaction TimexGroup (F(5,127) = .760, p = .580)); Theta Time (F(1,127) = .232, 
p = .631)) or interaction TimexGroup (F(5,127) = 1.030, p = .403)); Alpha Time 
(F(1,127) = .591, p = .002)) or interaction  Alpha TimexGroup (F(5,127) = .061, p 
= .079)); Beta Time (F(1,127) = .010, p = .921)) or interaction TimexGroup 
(F(5,127) = .492, p = .781)); Low Gamma Time (F(1,127) = .025, p = .875)) or 
interaction TimexGroup (F(5,127) = .272, p = .927)); High Gamma Time (F(1,127) 
= .097, p = .756)) or interaction TimexGroup (F(5,127) = .299, p = .913)). 
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Figure 7. Coherence analysis between PFC-vHPC activity A) Delta coherence. B) Theta 
coherence. C) Alpha coherence. D) Beta coherence. E) Low gamma coherence. F) High gamma 
coherence. Sample size: Vehicle (N=20), THC 100ng (N=21), CBD 100ng (N=33), THC+CBD 
100ng:100ng (N=21), THC+CBD 100ng:500ng (N=21), CBD 500ng (N=17).   
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4. Discussion 
 
4.1 PFC single unit activity is altered by THC but prevented by co-
administration of CBD 
 
Previous findings from this research group have already demonstrated that 
a full agonist for the CB1R in the BLA can alter the single unit activity of neurons 
in the PFC (Tan et al. 2010; Tan et al., 2011). Given these findings, we performed 
a series of in vivo single unit recordings in both the PFC and vHPC and 
investigated the effects of the partial CB1R agonist THC in the BLA. Our analyses 
revealed that micro-infusions of THC caused an increase in pyramidal cell firing 
and bursting rates in the PFC.  
 
The majority of CB1R expression in the BLA is located on interneuron 
populations (Marsicano & Lutz, 1999). Furthermore, application of 
endocannabinoid agonists on BLA interneurons reduces spontaneous evoked 
activity, which can potentially reduce overall inhibition on BLA pyramidal cell firing 
(Howlett et al., 1986; Sullivan 1999; Hoffman & Lupica, 2000; Wilson & Nicoll, 
2001; Kano et al., 2009). Given these findings, along with the present results, our 
proposed model suggests that THC increases activation of BLA pyramidal cell 
projections to increase spontaneous single unit activity in the PFC. Our lab has 
already shown that activation of BLA CB1R can potentiate non-salient stimuli 
during the acquisition of an emotional memory and create a conditioned place 
aversion of a morphine reward memory (Tan et al., 2010; Tan et al., 2011). As 
THC is a partial agonist of the CB1R, it is possible that micro-infusions into the 
BLA could also potentiate non-salient stimuli during emotional memory acquisition. 
Although we have not tested this in the BLA, THC micro-infusions into the NASh 
can potentiate the acquisition of a fear memory at sub-threshold levels of foot 
shock (Fitoussi et al., 2018). Given the well-known psychotropic effects associated 
with THC, it is possible that increasing activity of the BLA to alter PFC activity leads 
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to misattributing the salience of normal objects in the environment, a behaviour 
that is commonly found in psychosis and schizophrenia (Laviolette & Grace, 2006).  
 
Next, we investigated whether the combination of THC with CBD at a ratio 
of 1:1 and 1:5 would block the effects of THC. In both cases, micro-infusions of the 
combination prevented PFC pyramidal cell increases as seen with THC. In 
addition, CBD at 100 and 500ng did not alter PFC activity compared to vehicle. 
While there yet exists a clear mechanism to explain how CBD can reverse the 
effects of THC, a number of studies have demonstrated the potential therapeutic 
advantage of the formulated dose. In rodents, systemic combinations of 1:1 or 1:3 
can prevent THC induced conditioned place aversion or deficits associated with 
social interaction (Vann et al., 2008; Malone et al., 2009). In humans, a 1:2 oral 
dose can prevent impairments in affect recognition induced by THC (Hindocha et 
al., 2015). Current research has yet to investigate how the combined dose can 
interact in specific regions of the brain. The current findings are the first to 
demonstrate that a combined THC+CBD formulation blocks electrophysiological 
changes induced by THC in the brain. 
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Figure 8A. Proposed model of BLA cannabinoid transmission on PFC activity. THC into the BLA 
binds to CB1Rs that are primarily located on GABA interneuron populations. Activating these 
receptors inhibits neurotransmitter release on terminals, therefore causing an overall dis-inhibition 
of BLA pyramidal cell activity. Increases in BLA activity are associated with changes to PFC 
pyramidal cell targets, which are associate with increases in single unit firing, bursting, and LFPs 
for high frequency gamma. The THC+CBD formulation is sufficient to prevent these effects. The 
mechanism for how these two compounds interacts is still not clear.   
 
4.2 Cannabidiol decreases single unit activity in the vHPC 
 
In the vHPC, THC micro-infusions did not alter single unit pyramidal cell 
activity compared to vehicle. Previous findings have demonstrated systemic THC 
infusions show no change in pyramidal cell firing (Aguilar et al., 2016). It is possible 
that the dose used in the current study was not high enough to induce an 
electrophysiological change in the vHPC, as a higher dose of BLA THC infusions 
(1ug) have been associated with anxiolytic effects (Rubino et al., 2008). In contrast 
to results in the PFC, CBD micro-infused in the BLA caused a decrease in vHPC 
single unit activity. Surprisingly, this effect was still present when CBD was 
combined with THC.  
 
8A 
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Interestingly, intracranial infusions of CBD into the NASh, at this same dose, 
have previously been shown to attenuate single unit activity of dopamine neurons 
in the VTA (Norris et al., 2016; Renard et al., 2016). The application of a 5HT-1A 
antagonist while co-administered with CBD was sufficient to prevent this effect, 
supporting the 5HT-1A serotonin receptor as one of its main sites of action (Norris 
et al., 2016; Russo et al., 2005). Activation of the 5HT-1A receptor can cause the 
inhibition of postsynaptic action potentials, therefore decreasing the cell’s firing 
output (Polter & Li, 2010; Tada et al., 2004). With the current project’s findings, our 
proposed model suggests that CBD, via activation of the 5HT-1A receptors on BLA 
pyramidal cells, inhibits principal cell firing rates in the vHPC. Using patch-clamp 
recordings, researchers have demonstrated that inactivating BLA projections to 
vHPC pyramidal cells causes decreased cell firing because of a decrease in 
glutamate release (Felix-Ortiz et al., 2013). It is possible that CBD inhibits output 
of BLA pyramidal cell activity to the vHPC by decreasing glutamate release. 
Inactivating these pathways is related to social and anxiety-related behaviour 
changes (Felix-Ortiz et al., 2013; Felix-Ortiz & Tye, 2014). Further research should 
investigate whether CBD in the BLA is sufficient to alter similar behaviours through 
inactivating projections to the vHPC. 
 
 
9A 
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Figure 9A. Proposed model of BLA cannabinoid transmission on vHPC activity. CBD infused into 
the BLA binds to 5-HT1A receptors located on the soma and dendrites of pyramidal cells. Activating 
these receptors is associated with reduced EPSP generation to reduce overall action potential 
firing. This causes a decrease in pyramidal output to vHPC principal neurons, therefore reducing 
the overall activity of these cells. Surprisingly, the combination with THC is insufficient to prevent 
this effect, indicating this pathway’s potential preference for CBD. Independent of CBD, THC within 
the BLA does not increase vHPC single unit or LFP activity. 
 
4.3 Cannabinoid transmission alters cortical LFP activity 
 
In contrast to cell-specific firing rates, we next investigated measures of 
indirect changes in cell input with LFPs. Analysis across oscillation ranges 
revealed that BLA THC caused an increase in power for gamma oscillations, with 
the strongest effect seen at the higher frequency (62-80Hz). Furthermore, the 
combination with CBD prevented this effect and returned post-infusion power 
changes similar to vehicle. The application of BLA CBD did not alter LFP signals 
compared to vehicle. In the vHPC neither THC, CBD, nor the combination led to 
changes in any oscillation patterns. 
 
Coordination of cortical gamma oscillations integrate brain functions 
associated with cognitive and sensory processing (Basar et al., 2001). 
Disturbances in this network can potentially make the brain vulnerable to 
behavioural abnormalities. Network gamma oscillations in rodents are altered by 
activation of the CB1R, leading to alterations in impairments of cognitive and 
sensory processes (Hajos, Hoffmann, & Kocsis, 2008). As well, systemic 
application of THC in both adolescent and adult rodents have previously been 
shown to alter power for high frequency oscillations (Renard, 2017a; Robbe et al, 
2006).  
 
One neuropathological feature of schizophrenia is the disturbance of PFC 
gamma oscillations, leading to increased hallucinations and deficits in cognitive 
processes (Lee et al., 2010; Symond et al., 2005). In healthy subjects, acute THC 
administration has been associated with increase gamma activity and is correlated 
with increases in symptoms associated with psychosis (Nottage et al., 2015). 
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Therefore, THC’s negative effects can potentially act through alterations in the 
gamma oscillation range. We demonstrate that a combination of CBD may act to 
prevent these disturbances, as the literature suggests a  therapeutic benefit of 
higher CBD to THC ratios (Boggs et al., 2017). 
 
4.4 BLA cannabinoid transmission does not alter PFC-vHPC connectivity.  
 
For the final set of data, we performed an exploratory analysis investigating 
PFC-vHPC connectivity across both general activity (Crosscorrelation) and within 
oscillations (Coherence). The crosscorrelation takes the average shape of the LFP 
signal within a five-minute baseline period. The average shape within the vHPC is 
applied on top of the average shape of the PFC LFP signal. The degree of overlap 
on both signals is then assigned a correlation value, with the highest 
crosscorrelation 1.0 meaning the signals completely overlap. Coherence is a 
similar method, but it looks at comparing the degree of vHPC to PFC signal overlap 
as a function of frequency (Delta, Theta, Alpha, Beta, & Gamma). In both 
crosscorrelation and coherence analysis, post-infusion values are compared 
against baseline values to determine if any significant differences exist between 
treatment groups. 
 
In both data sets, micro-infusions of THC, CBD, or the combination in the 
BLA did not cause any significant differences. Our findings are consistent with 
previous research that showed systemic THC does not alter Theta or Gamma 
oscillations, although researchers show increased Delta coherence in awake 
animals (Aguilar et al., 2016). Our findings suggest that while cannabinoid 
transmission in the BLA is sufficient to alter single-unit and LFP activity, it does not 
alter the coordination between brain regions. Future studies should explore 
whether a higher dose of THC or the application of a full CB1R agonist can change 
the coordinated activity between regions. 
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4.5 Implications 
 
The current thesis adds to the literature on cannabinoid transmission within 
the mesolimbic system. Specifically, this is the first study to demonstrate that a 
combination of THC+CBD is enough to negate the effects of THC on 
electrophysiological activity of mesolimbic brain areas. Within regions of the BLA, 
PFC, and vHPC, our research group has demonstrated that THC or the activation 
of its target receptor, CB1R, can impair cognition, anxiety, sociability, learning and 
memory, and reward-related behaviours (Ahmad et al., 2016; Draycott et al., 2014; 
Loureiro et al., 2015; Loureiro et al., 2016; Renard et al., 2017a; Renard et al., 
2017b; Tan et al., 2010, Tan et al., 2011). Current literature suggests the 
combination of THC and CBD can reverse some of these impairments, although 
the exact mechanism is still not understood (Boggs et al., 2018).  
 
The model presented in Figures 8 and 9 can potentially explain these 
effects. Activation of CB1R in the BLA increases the activity of PFC pyramidal 
cells, which can potentiate the processing of emotionally neutral stimuli (Tan et al., 
2010; Tan et al., 2011). Furthermore, increased activity of cortical gamma 
oscillations can impair cognition and produce acute deficits, as seen in 
schizophrenia (Lee et al., 2010, Nottage et al., 2015; Renard et al., 2017a; Symond 
et al., 2005). In our current study, the combination of THC+CBD in the BLA blocked 
this overexcitation of PFC activity. Overexcitation of the vHPC has also been 
implicated in modulating the mesolimbic system to produce schizophrenic-like 
deficits (Grace et al., 2010). Although we were surprised to find THC did not 
increased activity in this region, CBD with or without THC decreased overall 
principal neuron activity in the vHPC. These findings are supported in healthy 
human populations, in which oral administration of CBD decreases resting state 
activity within the amygdala and ventral hippocampus (De Crippa et al., 2004). 
Given how CBD interacts with the 5HT-1A receptor, decreased BLA pyramidal cell 
firing is responsible for inducing a decrease in vHPC activity. Our findings provide 
a novel avenue for investigating the anti-psychotic-like benefits of CBD because 
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of its ability to alter the vHPC. Modulating the mesolimbic system through 
cannabinoid transmission may partially be responsible for inappropriately 
reinforcing the distorted emotional significance of everyday events within the 
schizophrenic population (Laviolette & Grace, 2006). The combined use of 
THC+CBD can potentially mitigate this impact on the mesolimbic system by 
simultaneously preventing overexcitation of cortical and hippocampal activity. 
 
5. Limitations   
 
Although our findings demonstrate a clear relationship between BLA 
cannabinoid transmission and its effects on the PFC and vHPC, more experiments 
are needed to better characterize this circuitry. In particular, we could not 
demonstrate whether cells recorded in either region were directly or indirectly 
affected by afferent projections from the BLA. For instance, BLA projections not 
only synapse on pyramidal cell populations but also on GABAergic interneuron 
populations. Associated changes in either region in this study could be mediated 
by altering activity in interneuron populations. Increase of cortical GAMMA 
oscillations are mediated in part by dysregulation of local interneuron populations 
(Buzsaki & Wang, 2012). A follow-up project should investigate whether the effects 
seen with infusions made into the BLA directly interfere with the PFC or vHPC or 
are mediated from a different cell. One method to determine this is orthodromic 
validation. This would require recording in the BLA to PFC or vHPC innervation 
before drug infusion. In this paradigm, experimenters would stimulate neurons in 
PFC or vHPC target regions, which would conduct back up the axon of a BLA 
pyramidal cell. When co-stimulation of BLA and target structures negate the other 
area’s conduction, the recorded cell is interpreted as a direct projection. 
Furthermore, recordings of interneuron populations within the vHPC or PFC would 
indirectly provide detail as to whether THC or CBD may have an indirect effect. In 
the case of VTA dopamine neurons, previous research has demonstrated changes 
via nucleus accumbens CBD infusions to be mediated by changes in VTA 
interneuron activity (Norris et al., 2016).  
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In the present study, THC did not cause a change in vHPC recorded 
neurons. One limitation to this interpretation was that we only used one dose of 
THC. In the case of CBD, two doses were used to confirm its effects. It is possible 
that a higher dose of THC can still cause a change in vHPC activity, given how 
previous studies have used BLA infusions of 1ug and above (Rubino et al., 2008). 
Despite this, our dose was still sufficient to elicit a change in PFC activity. Follow-
up research should include a low THC dose (10 ng) that has not elicited any 
behavioural or electrophysiological changes in rodents (Norris et al., 2016). By 
adding a lower dose, future research can determine the lower bound of BLA THC 
infusions that cause electrophysiological changes. 
 
Future Directions 
 
We demonstrated the reversal effects of a combined THC+CBD 
formulation, however we have yet to demonstrate the underlying mechanism 
behind this. Although CBD has opposite effects on the CB1R compared to THC, 
CBD’s overall low affinity for this receptor suggests that its main site of action is 
dependent on a different receptor (Pertwee, 2004). In this case, we could not 
determine which receptor type is responsible for the decreases found in the ventral 
hippocampus. Given the pharmacological binding profile of CBD, potential target 
receptors are 5-HT1A, D2, Mu opioid, or GPR55 (Kathmann et al., 2016; Russo et 
al., 2005; Ryberg et al., 2007; Seeman, 2016). Previous research has already 
indicated that blockade of the 5-HT1A receptor prevents the effects of systemic 
and local CBD on emotional memory acquisition and changes in mesolimbic 
neuron firing (Katsidoni et al., 2009; Norris et al., 2016). Future research should 
combine CBD with a 5-HT1A antagonist to determine if CBD’s main site of action 
in the BLA is mediated by the serotonin receptor.  
 
Beyond electrophysiology, future studies should explore the independent 
and combined behavioural effects of THC and CBD. Activating BLA CB1R and 
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increasing PFC activity can potentiate non-emotionally salient stimuli to be 
encoded in a fear memory (Tan et al., 2010). In fear memory formation, CBD 
infused into the shell of the nucleus accumbens alone is sufficient to block 
acquisition (Norris et al., 2016). It is possible that the combination of THC+CBD 
can prevent potentiation of fear memory and can negate changes in cortical 
activity.  
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Conclusions 
 
Within the mammalian brain, the proper encoding of environmental stimuli 
is regulated by the cannabinoid system. Disruption of this system through cannabis 
can lead to either positive or negative effects, depending on the relative ratio of 
THC to CBD within the plant. Impaired cognition, anxiety, learning, and memory 
are associated with activation of the CB1R via THC in the BLA, vHPC, and PFC. 
Combining CBD with THC appears to prevent these acute impairments and could 
allow a user to avoid some of the negative effects associated with high amounts 
of THC. To test this question, we used in vivo electrophysiology to determine if 
THC+CBD can negate THC-induced overexcitation of PFC pyramidal cells. Not 
only was the combination effective, it simultaneously decreased ventral 
hippocampal activity, possibly another benefit to counter the effects of high THC. 
We demonstrate for the first time that THC+CBD has therapeutic benefits that are 
demonstrated through neuronal activity in mesolimbic areas of the brain.  
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